Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors

Chemotherapy
Yingying MaCheng Zhang

Abstract

With the advent of tyrosine kinase inhibitors (TKIs), the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has entered a new era. The efficacy of TKIs compared with other ALL treatment options is emphasized by a rapid increase in the number of TKI clinical trials. Subsequently, the use of traditional approaches, such as combined chemotherapy and even allogeneic hematopoietic stem cell transplantation (allo-HSCT), for the treatment of ALL is being challenged in the clinic. In light of the increased use of TKIs in the clinic, several questions have been raised. First, is it necessary to use intensive chemotherapy during the induction course of therapy to achieve a minimal residual disease (MRD)-negative status? Must a patient reach a complete molecular response/major molecular response before receiving allo-HSCT? Does MRD status affect long-term survival after allo-HSCT? Is auto-HSCT an appropriate alternative for allo-HSCT in those Ph+ ALL patients who lack suitable donors? Here, we review the recent literature in an attempt to summarize the current status of TKI usage in the clinic, including several new therapeutic approaches, provide answers for the above questions, and speculate on the f...Continue Reading

References

Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Nov 3, 2007·The Lancet Oncology·Jane F Apperley
Jun 10, 2010·Bone Marrow Transplantation·C LinkerR Negrin
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanAlessandro Rambaldi
Jan 18, 2011·Hematology·Dario Campana
Jan 14, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Giovanni CaocciGiorgio La Nasa
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Nov 12, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sebastian GiebelMohamad Mohty
Apr 17, 2015·Blood·Yves ChalandonUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Aug 5, 2015·Journal of Hematology & Oncology·Seiichi OkabeKazuma Ohyashiki
Apr 29, 2016·Blood·Philippe RousselotUNKNOWN European Working Group on Adult ALL (EWALL) group

❮ Previous
Next ❯

Citations

Nov 10, 2020·Frontiers in Immunology·Nathaniel Edward Bennett SaiduSara Galimberti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.